CRON vs. WEED, TLRY, GUD, ACB, BHC, DNTL, SIA, WELL, EXE, and OGI
Should you be buying Cronos Group stock or one of its competitors? The main competitors of Cronos Group include Canopy Growth (WEED), Tilray Brands (TLRY), Knight Therapeutics (GUD), Aurora Cannabis (ACB), Bausch Health Companies (BHC), dentalcorp (DNTL), Sienna Senior Living (SIA), WELL Health Technologies (WELL), Extendicare (EXE), and Organigram (OGI). These companies are all part of the "medical" sector.
Canopy Growth (TSE:WEED) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, community ranking, risk, media sentiment, profitability and institutional ownership.
In the previous week, Canopy Growth had 1 more articles in the media than Cronos Group. MarketBeat recorded 4 mentions for Canopy Growth and 3 mentions for Cronos Group. Canopy Growth's average media sentiment score of 0.78 beat Cronos Group's score of 0.73 indicating that Cronos Group is being referred to more favorably in the news media.
4.3% of Canopy Growth shares are held by institutional investors. Comparatively, 13.1% of Cronos Group shares are held by institutional investors. 0.2% of Canopy Growth shares are held by insiders. Comparatively, 46.6% of Cronos Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Canopy Growth has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Cronos Group has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.
Canopy Growth presently has a consensus price target of C$3.20, suggesting a potential downside of 74.96%. Cronos Group has a consensus price target of C$2.77, suggesting a potential downside of 32.60%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Canopy Growth.
Cronos Group has lower revenue, but higher earnings than Canopy Growth. Cronos Group is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth received 571 more outperform votes than Cronos Group when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 51.11% of users gave Cronos Group an outperform vote.
Canopy Growth has a net margin of 0.00% compared to Canopy Growth's net margin of -84.78%. Canopy Growth's return on equity of -6.30% beat Cronos Group's return on equity.
Summary
Cronos Group beats Canopy Growth on 10 of the 17 factors compared between the two stocks.
Get Cronos Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CRON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cronos Group Competitors List
Related Companies and Tools
